Show simple item record

dc.contributor.authorSewell, GJ
dc.date.accessioned2015-10-27T16:16:54Z
dc.date.available2015-10-27T16:16:54Z
dc.date.issued2010
dc.identifier.urihttp://hdl.handle.net/10026.1/3710
dc.description.abstract

Study objectives: To determine the extended chemical and physical stability of cisplatin infusions in PVC containers at normal in-use concentrations in saline, with and without added electrolyte combinations relevant to clinical practice.

Methods: Cisplatin infusions 0.1-0.4 mg/mL were prepared in normal saline, with and without magnesium sulphate and potassium chloride supplements in 500 mL PVC bags, and stored at 25°C protected from light. Chemical stability was assessed by a stability-indicating LC method. Evidence for precipitation was detected by a light-blocking particle count method for sub-visible particles, supported by visual examination. pH and weight changes were also monitored for at least 28 days.

Results: Both 0.1 mg/mL and 0.4 mg/mL infusions, with or without the added electrolyte supplements, were chemically stable over 28 days at 25°C. The pH of infusions varied by no more than 0.2 units over this time, there was no visible precipitation, and no significant changes in sub-visual particulate levels or infusion weight. The study was restricted to 28 days because small, visual precipitation was evident in some infusions after 25 days.

Conclusion: Cisplatin infusions at concentrations ranging from 0.1-0.4 mg/mL, in 500 mL PVC bags containing either 0.9% sodium chloride or 0.9% sodium chloride + 20 mmoL KCI + 8 mmoL MgSO₄ were physically and chemically stable for up to 28 days at 25°C, when protected from light. Extending shelf lives beyond this period is unsafe due to the potential development of precipitates.

dc.format.extent11-13
dc.language.isoen
dc.titlePhysical and chemical stability of cisplatin infusions in PVC containers
dc.typejournal-article
dc.typeArticle
plymouth.edition2010
plymouth.issue1
plymouth.volume4
plymouth.publication-statusPublished
plymouth.journalEuropean Journal of Oncology Pharmacy
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Health Professions
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy MANUAL
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Health and Community
plymouth.organisational-group/Plymouth/Users by role
dcterms.dateAccepted2010-01-01
dc.rights.embargoperiodNot known
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV